Comparison
Fisetin vs Hexarelin
Side-by-side of Fisetin and Hexarelin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Fisetin
Fisetin is a flavonoid found in strawberries with senolytic activity in mouse models. Hickson 2019 confirmed senescent-cell clearance in human adipose tissue.
Hexarelin
Hexarelin peptide is a ghrelin-receptor hexapeptide. Largest acute GH pulse in the GHRP class, highest cortisol and prolactin lift, CD36 cardioprotective sign.
Effects at a glance
Fisetin
- •Flavonoid found in strawberries; most potent natural senolytic in screening assays (Yousefzadeh 2018)
- •Hickson 2019 confirmed reduced senescent-cell burden in human adipose tissue at 20 mg/kg pulsed for 2 days
- •Pulsed Mayo protocol (20 mg/kg/day x 2 days monthly) is the only dose with human biomarker evidence
- •Daily low-dose (100-500 mg) is mechanistically weaker but commonly used
- •Low oral bioavailability; with-fat dosing modestly improves absorption
- •Active cancer is a relative contraindication pending clearer polyphenol-treatment data
Hexarelin
- •Synthetic hexapeptide GHS-R1a agonist; produces the largest acute GH pulse of the synthetic GHRP class
- •Independent CD36 signaling produces cardioprotective effects in rodent ischemia models, GH-independent
- •Pronounced tachyphylaxis: GH response attenuates over 2 to 4 weeks of daily dosing
- •More cortisol and prolactin elevation than GHRP-2 or ipamorelin
- •Anecdotal protocols use 100 to 200 mcg subcutaneously 1 to 2 times daily for 2 to 4 week pulses
- •Banned by WADA under S2; advanced through phase 2 trials but never reached registration
Side-by-side
| Attribute | Fisetin | Hexarelin |
|---|---|---|
| Category | supplement | peptide |
| Also known as | 3,7,3',4'-tetrahydroxyflavone | Examorelin, EP-23905, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 |
| Half-life (hr) ↗ | 2 | 1 |
| Typical dose (mg) ↗ | 500 | 0.1 |
| Dosing frequency | pulsed 2 days/month (Mayo protocol) or daily continuous (empirical) | 1-2x daily |
| Routes | oral | subcutaneous, intranasal, intravenous |
| Onset (hr) | 1 | 0.25 |
| Peak (hr) | 4 | 0.5 |
| Molecular weight | 286.24 | 887.04 |
| Molecular formula | C15H10O6 | C47H58N12O6 |
| Mechanism | Senolytic via Bcl-2 family inhibition (Bcl-xL, Bcl-w); broad polyphenol with Nrf2 activation, mTOR inhibition at high concentrations, and antioxidant effects. | Hexapeptide agonist of GHS-R1a producing acute GH release with cortisol and prolactin co-elevation. Independent CD36 binding produces GH-independent cardioprotective signaling in preclinical models. |
| Legal status | OTC dietary supplement | Not FDA approved; advanced through phase 2 trials in EU but never registered; research-use-only grey market; banned by WADA |
| WADA status | allowed | banned |
| DEA / Rx | OTC supplement | Not scheduled (research chemical) |
| Pregnancy | Insufficient data | Insufficient data; not recommended |
| CAS | 528-48-3 | 140703-51-1 |
| PubChem CID | 5281614 | 3037387 |
| Wikidata | Q230614 | Q5743550 |
Safety profile
Fisetin
Common side effects
- mild GI upset
- headache (rare)
Contraindications
- active cancer (theoretical, polyphenol interactions)
- pregnancy and lactation (insufficient data)
- concurrent CYP3A4-sensitive medications
Interactions
- statins (CYP3A4 substrates): theoretical reduction in statin clearance at high fisetin doses(minor)
- warfarin: theoretical CYP-mediated interaction; monitor INR if combining(moderate)
- other senolytics (rapamycin, dasatinib + quercetin): additive senolytic effect; pairing is investigational(minor)
Hexarelin
Common side effects
- water retention
- vivid dreams
- head pressure or flushing
- transient lethargy
- tingling at injection site
- moderate hunger
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
- prolactin-sensitive states
Interactions
- CJC-1295: synergistic GH release; accelerates tachyphylaxis if used continuously(minor)
- sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: amplify cortisol load; blunt GH response(moderate)
Which Should You Take?
Fisetin comes out ahead for most readers on the criteria we weight: 2 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Hexarelin is the right call when one of the conditionals below applies.
- → If your priority is healthspan extension, pick Fisetin.
- → If your priority is focus or working memory, pick Fisetin.
- → If your priority is growth-hormone axis, pick Hexarelin.
- → If your priority is post-training recovery, pick Hexarelin.
Edge case: If you want to avoid research-only / gray-market sourcing, Fisetin is the more accessible choice.
Default choice: Fisetin. Lower friction to source, and broader goal coverage. Reach for Hexarelin only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Fisetin and Hexarelin?
Fisetin and Hexarelin differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Fisetin or Hexarelin?
Fisetin half-life is 2 hours; Hexarelin half-life is 1 hours.
Can you stack Fisetin with Hexarelin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper